Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern.
Avery
Robert L
RL
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D000069579:Ranibizumab; D012164:Retinal Diseases / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab